New drug targets immune cells in scalp psoriasis
NCT ID NCT05858632
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests how guselkumab, a drug that blocks IL-23, affects immune cells in scalp psoriasis lesions. Ten adults with moderate-to-severe scalp psoriasis will receive treatment and have their scalp severity scores measured before and during treatment. The goal is to understand how the drug works on the immune system to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS OF SCALP are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.